Bio-Rad Laboratories, Inc., Abbott, Siemens Healthineers AG are dominating the Global Diabetic Assays Market in 2019

Diabetic Assays Market is expected to grow with the CAGR of 4.3% in the forecast period 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report at https://www.databridgemarketresearch.com/reports/global-diabetic-assays-market

Diabetic assays market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased various strategic developments owing to favourable market scenario.

The major players dealing in global diabetic assays market are introducing strong range of product portfolio. This has also helped the company to maximize the sales with enhanced product portfolio. For instance, In March 2019, Beckman Coulter, Inc, hemoglobin A1c (HbA1c) Advanced assay received C E Mark Certification and the U.S. FDA 501(k) Clearance. Through this achievement, the company will offer initial diagnosis of diabetes and will also deliver the clinically operative outcomes.

Bio-Rad Laboratories, Inc. is the dominating player in the diabetic assays market, which is followed by Abbott, Siemens Healthineers AG, DiaSorin SpA. The other key players existing in the Merck KGaA, EKF Diagnostics, DRG INSTRUMENTS GMBH, PTS Diagnostics, Ortho Clinical Diagnostics, Medipan GmbH, Diagnostic Automation/Cortez Diagnostics Inc., Diazyme Laboratories, Inc., Ethos Biosciences, Inc., BioAssay Systems, Tosoh Corporation, Abnova Corporation, Monobind Inc, ORGENTEC Diagnostika GmbH, ALPCO among others

Bio-Rad Laboratories, Inc.:

Bio-Rad Laboratories, Inc. headquartered in California, U.S. was founded in 1952. The company focuses on development, manufacturing of innovative products for the life science research and clinical diagnostic sectors. The company is providing product under life science research, clinical diagnostics, spectroscopy, process separations, food science, and life science education category. The company is continuously engaged in manufacturing and development of diabetic assays.

• In July 2017, the company received approval from the FDA for D-10 Hemoglobin A1c Program, a diagnostic product which will provide accurate test results and early diagnosis for patient health improvement. Through this, the company has expanded its product offering and will also provide diagnosis and identification for the patients at risk of developing the diabetes at an earlier stage.

It has its global networks through direct sales representatives and distributors in Asia-Pacific, Europe, Middle East and Africa, South America, North America through its subsidiaries in bio-rad abd serotec limited (U.S.), DiaMed Holding AG (Switzerland), QuantaLife, Inc.(U.S.), GnuBIO, Inc.(U.S.), Bio-Rad Laboratories S.r.l. (U.S.) among others.

Abbott:

Abbott headquartered in Illinois, U.S. was founded in 1888. The company is focused on providing products and services for cardio metabolic disease, infectious disease and toxicology. The company is providing GLP Systems, ACCELERATOR, Architect, CELL-DYN, Alinity, AlinIQ, FreeStyle, ALERE brands. The company is operating in established pharmaceuticals, nutritionals, diagnostic, cardiovascular and neuromodulation segments. The market focus product lies under diagnostic segments.  The company is continuously engaged in manufacturing and developments of diabetic assays.

For instance,

• In June, 2019, Abbott has launched its first rapid point-of-care HbA1c test to diagnose diabetes “Afinion HbA1c Dx assay” for use on Afinion AS100 Analyzer and Afinion 2 Analyzer. The Afinion HbA1c Dx assay is the first and rapid point-of-care method approved by the U.S. Food and Drug Administration (FDA) to support health professionals in the diagnosis and treatment of diabetes. This launch will expand product portfolio as well as user base of the company.

The company has wide global presence across the globe such as Europe, Asia-Pacific, Middle East & Africa, and Americas. In addition to it, the company also generates its revenue from the various subsidiary companies such as Abbott Administration Inc (Delaware), Abbott Cardiovascular Systems Inc. (California), Abbott Home Infusion Services of New York, Inc.(New York), Abbott Laboratories (Puerto Rico) Incorporated, EAS Australia Pty Ltd (Australia), Abbott (Cambodia) LLC, Abbott Laboratories A/S (Denmark) among others.

Siemens Healthineers AG:

Siemens Healthineers AG has headquartered in Erlangen, Germany. The company offers technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics and molecular medicine as well as digital health and enterprise services. The company is providing product under medical imaging, laboratory diagnostics, point-of-care testing, services, healthcare IT, clinical specialties, accessories, OEM & electronics categories.  The company engaged in business expansion of diabetic assays products.

• In January 2019, Siemens Healthineers AG introduced its wide range of products and services at MedLab Middle East 2019 in its main areas of laboratory diagnostics and molecular medicine. MedLab is the only medical laboratory operation that offers vendors a chance to meet a diverse audience of customers. More than 19,610 health labs and practitioners from manufacturers to senior end-users accepted the 2019 version in the search for the latest innovative products. With this exhibition, the company has shown their products to extend its market global presence in field of in-vitro diagnostics.

The company has presence in Europe, Asia-Pacific, North America, South America, Middle East and Africa. In addition to it, the company also generates its revenue from the various subsidiary companies such as Siemens Healthcare SAS (France), Dedicated2Imaging LLC, (United States), Acrorad Co., Ltd., (Japan), Siemens Healthcare d.o.o., (Croatia) and Siemens Healthcare Nederland B.V. (Netherlands) among others.

Recent Strategic Decisions